Alliance pharmaceutique pancanadienne (APP) – dernières mises à jour

État Nombre total Résumé
En négociation 45 Non liées à l’oncologie : 29
Liées à l’oncologie : 16
Négociations envisagées 17 Non liées à l’oncologie : 11
Liées à l’oncologie : 6
Négociations terminées 918 Avec lettre d’intention : 792
Sans entente : 126
Négociations qui n’ont pas eu lieu 113

Activités de l’APP dans les quatre dernières semaines

Voici les activités des quatre dernières semaines. Veuillez prendre note que le traitement de ces mises à jour peut prendre d’une à deux semaines.

Lettres d’engagement transmises au cours des quatre dernières semaines

Marque Fabricant Indication Date d’engagement
Blenrep (belantamab mafodotin) GlaxoSmithKline Inc. For the treatment of multiple myeloma in combination with pomalidomide and dexamethasone (Bpd) in adult patients who have received at least one prior therapy including lenalidomide.
Dupixent Sanofi Genzyme Canada Indicated as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils inadequately controlled by the combination of an inhaled corticosteroid (ICS), a long-acting beta2-a
Blenrep (belantamab mafodotin) GlaxoSmithKline Inc. For the treatment of multiple myeloma in combination with bortezomib and dexamethasone (BVd) in adult patients who have received at least one prior therapy.
Yondelis Xediton Pharmaceuticals Inc in combination with doxorubicin as first-line treatment for advanced unresectable or metastatic uterine or soft tissue leiomyosarcoma
Enhertu AstraZeneca Canada Inc. Advanced or Metastatic Gastric Cancer or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Rinvoq AbbVie Corporation Giant Cell Arteritis

Négociations achevées dans les quatre dernières semaines avec une lettre d’intention

Marque Fabricant Indication Date d’engagement Date d’achèvement
Vanflyta Daiichi Sankyo Pharma Canada In combination with standard cytarabineand anthracycline induction and standard cytarabine consolidationchemotherapy, and as continuation maintenance monotherapy followingconsolidation, for the treatment of adult patients with newly diagnosed acutemyeloid
Imfinzi AstraZeneca Canada Inc. ​In combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant durvalumab monotherapy, for the treatment of adult patients with resectable gastric or gastroesophage
Imfinzi AstraZeneca Canada Inc. in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment
Imfinzi AstraZeneca Canada Inc. Treatment of patients with resectable muscle invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by adjuvant IMFINZI monotherapy treatment after radical cystectomy.
Imfinzi-Imjudo AstraZeneca Canada Inc. In combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
Imfinzi AstraZeneca Canada Inc. For the treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).
Verzenio Eli Lilly Canada Inc. For the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer as follows: • in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy. • in combination with fulvestrant in women with disea
Verzenio Eli Lilly Canada Inc. For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor (AI) in postmenopausal women as initial endocrine-based therapy.

Négociations achevées dans les quatre dernières semaines sans entente

Marque Fabricant Indication Date d’engagement Date d’achèvement

No negotiations completed without agreement in the last four weeks

Négociations que l’APP a décidé de ne pas entreprendre dans les quatre dernières semaines

Marque Fabricant Indication Aucune date de négociation

Négociations que l’APP a décidé de ne pas entreprendre dans les quatre dernières semaines